Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$91.00K$91.00Kderived−38.1% vs Q4 2017 Net Income-$4.42M-$4.42MderivedN/M vs Q4 2017 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$3,946,000N/M Operating Cash Flowderived-$3,375,000N/M Free Cash Flowderived-$3,597,000N/M Margins · derivedOperating margin-4336.3%−1711.1 pt vs Q4 2017
Net margin-4854.9%−1910.0 pt vs Q4 2017
ended Jun 30, 2018 · filed Sep 18, 2018 · 80 d after period end